Echo Therapeutics, Inc. operates as a medical device company with expertise in advanced skin permeation technology. The company is in the process of developing its Symphony CGM System (Symphony) as a non-invasive, wireless continuous glucose monitoring (CGM) system for use in hospital critical care units and for people with diabetes. The Prelude SkinPrep System (Prelude), a component of its Symphony CGM System, allows for enhanced skin permeation that would enable extraction of analytes such as glucose. Prelude’s platform skin preparation technology also allows for needle-free, transdermal drug delivery. Additional applications for needle-free analyte extraction and topical and systemic drug delivery are planned. Products Symphony CGM System The company’s main medical device program is Symphony, a non-invasive (needle-free), wireless, continuous glucose monitoring system designed to provide real-time glucose data. The Symphony CGM System incorporates a Prelude skin preparation device, transdermal sensor, wireless transmitter and data display monitor. When the electro-chemical glucose sensor is placed on the prepared site, it uses glucose oxidase to generate a continuous that is proportional to the concentration of blood glucose in the vessels beneath the epidermis. The signals are then wirelessly transmitted to a remote monitor. The monitor, calibrated periodically with a reference blood glucose measurement, converts the data to a glucose measurement based on the reference value. The monitor displays glucose readings and rates of increase and decrease, and also contains customizable early-warning alarms for hypo- or hyperglycemia. Agreement with Handok Pharmaceuticals: In 2009, the company entered into a license agreement with Handok Pharmaceuticals Co., Ltd. (Handok), a diabetes care-focused pharmaceutical company in South Korea. Under the terms of the agreement, the company granted Handok the right to develop, market, sell and distribute Symphony to medical facilities and individuals in South Korea. Prelude SkinPrep System The company is in the process of developing Prelude as a safe, effective, easy-to-use and low-cost transdermal skin preparation device for Symphony to enhance access to the interstitial fluids and enhance the flow of molecules across the protective membrane of the stratum corneum, the outmost protective layer of the skin. Prelude incorporates its patented skin abrasion control technology into a hand-held device used to prepare a small area of the skin. The non-invasive sensor is applied to this prepared area in order to measure the interstitial glucose levels. Prelude’s proprietary, patented feedback control mechanism consists of software, a microprocessor controlled circuit and measuring electrodes. Agreement with Ferndale Pharma Group: During 2009, the company entered into a licensing agreement with Ferndale Pharma Group, Inc. (Ferndale), a group of companies that specialize in the development, manufacture, distribution and marketing of various dermatologic products. Under the terms of the agreement, the company granted Ferndale the right to develop, market, sell and distribute Prelude for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures. In addition to the original territory of North America and the United Kingdom, the license agreement was amended in 2012 to cover South America, Australia, New Zealand, Switzerland and portions of the European Community. Specialty Pharmaceuticals The company’s specialty pharmaceuticals pipeline is based on its proprietary AzoneTS transdermal drug reformulation technology. AzoneTS is a nontoxic, nonirritating skin penetration enhancer that is intended to enable topical application of FDA-approved drugs, including pharmaceutical products that could only be administered systemically. AzoneTS increases lipid membrane fluidity in the stratum corneum layer of the skin, thereby decreasing resistance to topically applied therapeutics. The company’s proprietary synergistic chemical combination enables AzoneTS to be a highly effective skin penetration enhancer at low concentration levels. The company’s most advanced drug candidate is Durhalieve, an AzoneTS formulation of triamcinolone acetonide, a widely-used, medium potency corticosteroid approved by the United States Food and Drug Administration for treatment of corticosteroid-responsive dermatoses. The company holds Investigational New Drug Applications for methotrexate-AzoneTS (MAZ) formulations for the treatment of psoriasis and mycoses fungoides. The company has completed Phase 2 clinical studies of MAZ for the treatment of early-stage mycoses fungoides. Research and Development The company’s research and development expenses were approximately $8,671,000 for the year ended December 31, 2012. Intellectual Property As of March 2013, the company has 8 issued U.S. patents and at least 70 issued foreign patents, and the company has 5 U.S. patent applications and approximately 20 foreign patent applications pending. Its pharmaceutical patents begin expiring in 2019 and its medical device patents begin expiring in 2022. History Echo Therapeutics, Inc. was founded in 1989.
echo therapeutics inc (XS5A:Stuttgart)
8 Penn Center
1628 JFK Boulevard
Philadelphia, PA 19103
|Abbott Laboratories||$42.43 USD||+0.29|
|Bayer AG||€99.82 EUR||+0.66|
|Johnson & Johnson||$104.32 USD||+1.11|
|Roche Holding AG||SFr.265.60 CHF||+0.10|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ECHO THERAPEUTICS INC, please visit www.echotx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.